Proanthocyanidins inhibit In vitro and In vivo growth of human non-small cell lung cancer cells by inhibiting the prostaglandin e2 and prostaglandin e2 receptors

Molecular Cancer Therapeutics

Volumn 9, Issue 3, 2010, Pages 569-580

  Sharma, Som D ^a   Meeran, Syed M ^a   Katiyar, Santosh K ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; GRAPE SEED EXTRACT; INDOMETACIN; PROANTHOCYANIDIN; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GRAFT; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CELL DEATH; CELL PROLIFERATION; CELL STRAIN A549; CELL STRAIN H1299; CELL STRAIN H157; CELL STRAIN H226; CELL STRAIN H460; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIET; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CYCLOOXYGENASE 2; DINOPROSTONE; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; PROANTHOCYANIDINS; RECEPTORS, PROSTAGLANDIN E; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77949717864     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0638     Document Type: Article

References (37)

1. American Cancer Society. Cancer facts and figures 2007. Atlanta (GA): American Cancer Society; 2007.
2. Proctor RN. Tobacco and the global lung cancer epidemic. Nat Rev Cancer 2001;1:82-6.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2008;58:71-96.
4. Ferrigno D, Buccheri G. Second-line chemotherapy for recurrent non-small cell lung cancer: Do new agents make a difference? Lung Cancer 2000;29:91-104.
5. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005;128:452-62.
6. Garfinkel L, Silverberg E. Lung cancer and smoking trends in the United States over the past 25 years. CA Cancer J Clin 1991;41: 137-45.
7. Huang M, Stolina M, Sharma S, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998;58: 1208-16.
8. Hida T, Kozaki K, Muramatsu H, et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000;6:2006-11.
9. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-4.
10. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimäki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001.
11. Hosomi Y, Yokose T, Hirose Y, et al. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer 2000;30: 73-81.
12. Kutchera W, Jones DA, Matsunami N, et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci U S A 1996; 93:4816-20.
13. Fujita T, Matsui M, Takaku K, et al. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 1998;58:4823-6.
14. Kirschenbaum A, Liu X, Yao S, Levine AC. The role of cyclooxygenase-2 in prostate cancer. Urology 2001;58:127-31.
15. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000; 89:2637-45.
16. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 2002;277: 18649-57.
17. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
18. Lin MT, Lee RC, Yang PC, Ho FM, Kuo ML. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2001;276:48997-9002.
19. Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001;276:18075-81.
20. Dohadwala M, Luo J, Zhu L, et al. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 2001;276:20809-12.
21. Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta 1996;1299:125-40.
22. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003;4: 431-6.
23. Maziak DE, Markman BR, MacKay JA, et al. Cancer Care Ontario Practice Guidelines Initiative Lung Cancer Disease Site Group. Photodynamic therapy in non-small cell lung cancer: a systematic review. Ann Thorac Surg 2004;77:1484-91.
24. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000;355: 479-85.
25. Nandakumar V, Singh T, Katiyar SK. Multi-targeted prevention and therapy of cancer by proanthocyanidins. Cancer Lett 2008;269: 378-87.
26. Sharma SD, Meeran SM, Katiyar SK. Dietary grape seed proanthocyanidins inhibit UVB-induced oxidative stress and activation of mitogen-activated protein kinases and nuclear factor-κB signaling in in vivo SKH-1 hairless mice. Mol Cancer Ther 2007; 6:995-1005.
27. Mittal A, Elmets CA, Katiyar SK. Dietary feeding of proanthocyanidins from grape seeds prevents photocarcinogenesis in SKH-1 hairless mice: relationship to decreased fat and lipid peroxidation. Carcinogenesis 2003;24:1379-88.
28. Akhtar S, Meeran SM, Katiyar N, Katiyar SK. Grape seed proanthocyanidins inhibit the growth of human non-small cell lung cancer xenografts by targeting insulin-like growth factor binding protein-3, tumor cell proliferation, and angiogenic factors. Clin Cancer Res 2009;15:821-31.
29. 1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. Mol Cancer Ther 2006;5: 296-308.
30. Krysan K, Reckamp KL, Dalwadi H, et al. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res 2005;65:6275-81.
31. Riedl K, Krysan K, Põld M, et al. Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist Updates 2004;7: 169-84.
32. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-66.
33. Regan JW. EP2 and EP4 prostanoid receptor signaling. Life Sci 2003;74:143-53.
34. Lizcano JM, Morrice N, Cohen P. Regulation of BAD by cAMP-dependent protein kinase is mediated via phosphorylation of a novel site, Ser155. Biochem J 2000;349:547-57.
35. Shimamura H, Terada Y, Okado T, Tanaka H, Inoshita S, Sasaki S. The PI3-kinase-Akt pathway promotes mesangial cell survival and inhibits apoptosis in vitro via NF-κB and Bad. J Am Soc Nephrol 2003;14:1427-34.
36. Hoshino T, Tsutsumi S, Tomisato W, et al. Prostaglandin E2 protects gastric mucosal cells from apoptosis via EP2 and EP4 receptor activation. J Biol Chem 2003;278:12752-8.
37. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2007;22:659-61.